Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flucortac for Neurogenic Orthostatic Hypotension
2024-517841-16-00Phase 4Authorised
- Sponsor
- HAC Pharma
- Start
- Oct 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of fludrocortisone in Neurogenic Orthostatic Hypotension (nOH), sponsored by HAC Pharma. Planned start Oct 2024; status: authorised.
02
Drugs
fludrocortisone
03
Conditions
Neurogenic Orthostatic Hypotension (nOH)
Beyond the preview
Go deeper on 2024-517841-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517841-16-00.